Efficacy of low dose intra-dermal hepatitis B vaccination schedule

Journal of the Pakistan Medical Association

Volumn 48, Issue 12, 1998, Pages 377-378

  Zuberi, Bader Faiyaz ^a   Rajput, Muhammad Ramzan ^a   Muzaffar, Lala ^a   Jatoi, Noorunisa ^a   Shaikh, Wazir Muhammad ^a  

^a Chandka Medical College Hospital Shaheed Muhtarma Benazir Bhutto Medical University Larkana   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EUVAX; HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADULT; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INJECTIONS, INTRADERMAL;

EID: 0032322353     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kane M. Epidemiology of hepatitis B infection in North America. Vaccine, 1995;13:S16-17.
2. Kazmi K, Ghafoor A, Burney MI. Prevalence of HBsAg among blood donors of Islamabad. Pak. J. Med. Res., 1985;24:181-2.
3. Khadim MI. Prevalence of hepatitis B antigen in various population groups of NWFP. J. Pak. Med. Assoc. 1982;32:122-3.
4. Hallauer J. VHPB: Summary of strategies and recommendations. Viral Hepatitis Prevention Board. Vaccine, 1995;13 Suppl 1:S61-3.
5. Kane M. Global programme for control of hepatitis B infection. Vaccine, 1995;13:S47-9.
6. Goh KT, Oon CJ, Heng BH, et al. Long-term immunogenecity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults. Bull. WHO, 1995;73:523-7.
7. Keyserling HL, West DJ, Hesley TM, et al. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four and twelve or fifteen months of age. J. Pediatr. 1994;125:67-9.
8. Lee SS, Lo YC, Young BW, et al. A reduced dose approach to hepatitis B vaccination for low-risk newborns and preschool children. Vaccine, 1995;13:373-6.
9. Malik IA, Lukman M, Ahmed A, et al. Sporadic non-A, non-B hepatitis. A seroepidemiological study in Urban population. J. Pak. Med. Assoc, 1987;37:190-92.
10. Hall AJ, Roberston RL, Crivelli PE, et al. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans. R. Soc.Trop. Med. Hyg., 1993;87:333-6.
11. Garuz R, Torrea JL, Arnal JM, et al. Vaccination against hepatitis B virus in Spain: A cost-effectiveness analysis. Vaccine, 1997;15:1652-60.
12. Oddone EZ, Cowper PA, Hamilton JD, et al. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. Health Serv. Res., 1993;28:97-121.
13. Thompson SC, Darlington R, Tallent D. et al. Effectiveness of low-dose intradermal hepatitis B vaccination. Five year's experience of primary vaccination. Med. J. Aust, 1993;158:372-5.
14. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine, 1997;15:1618-23.
15. Elavia AJ, Marfatia SP, Banker DD, Immunization of hospital personnel with low-dose intradermal hepatitis B vaccine. Vaccine, 1994;12:87-90.
16. Chiaramonte M, Ngatchu T, Majori S, et al. Responseto an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization. Scand. J. Gastroenterol, 1995;30:601-3.
17. National advisory committee on immunization (NACI). Statement on hepatitis B vaccine, Can. Commun. Dis., Rep., 1993;19:104-15.